| Trial-Results center | |||
| Clinical trial results database |
 Feedback
 Home
|
This trial is included in the following systematic reviews and meta-analyses:
venous thrombosis
-
antithrombotics
-
all type of patients
venous thrombosis
-
heparin (UFH or LMWH)
-
all type of patients
Related trials
Lopaciuk, 3000 - subcutaneous heparin vs intravenous heparin
RE-COVER, 2009 - dabigatran vs vitamin K antagonists
Romera, 2009 - Tinzaparin vs acenocoumarol
Gonz�lez-Fajardo, 2008 - Enoxaparin vs coumarin
Botticelli DVT, 2008 - apixaban vs heparin/VKA
Einstein-DVT Dose-Ranging Study, 2008 - rivaroxaban vs heparin/VKA
VanGogh DVT, 2007 - idraparinux vs heparin/VKA
VanGogh PE, 2007 - idraparinux vs heparin/VKA
Daskalopoulos, 2005 - LMWH at home vs UFH in hospital
Fiessinger , 2005 - ximelagatran vs vitamin K antagonists
Chong, 2005 - LMWH at home vs UFH in hospital
Kearon, 2004 - 4 months vs 3 months
Ramacciotti, 2004 - LMWH at home vs UFH in hospital
MATISSE, 2004 - fondaparinux vs enoxaparin
Lee, 2003 - Dalteparin vs warfarin
Agnelli, 2003 - 6-12 months vs 3 months
Kakkar, 2003 - Bemiparin vs warfarin
Deitcher, 2003 - Enoxaparin vs warfarin
MATISSE PE, 2003 - fondaparinux vs heparin/VKA
Hull, 2002 - Tinzaparin vs warfarin
Meyer, 2002 - Enoxaparin vs warfarin
Agnelli, 2001 - 12 months vs 3 months
Merli (once daily vs UFH), 2001 - once daily enoxaparin vs UFH
Lopez-Beret, 2001 - Nadroparin vs acenocoumarol
Merli, 2001 - once daily enoxaparin vs twice daily enoxaparin
See also:
Gonz�lez-Fajardo study, 2008 |
|
Treatments
| Studied treatment |
long-term anticoagulant treatment with enoxaparin during at least 3 months
enoxaparin once daily in fixed doses (4000 anti-Xa units, 40 mg) |
| Control treatment |
long-term anticoagulant treatment with coumarin during at least 3 months
targetet international normalized ratio [INR], 2-3 |
Patients
| Patients | patients with symptomatic, unilateral, first-episode DVT |
Method and design
| Randomized effectives | 85 / 80 (studied vs. control) |
| Design | Parallel groups |
| Blinding | open, blind assessment |
| Follow-up duration | 1y, 5y |
| Number of centre | single center |
| Geographic area | Spain |
| Primary endpoint | incidence of post-thrombotic syndrome |
Results
n/N
n/N
VTE during active anticoagulant treatment
| Relative risks | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Endpoint | Events (%) | Relative Risk | 95% CI | Endpoint definition in the trial |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Studied treat. | Control treat. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| The primary endpoint (if exists) appears in blod characters | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Absolute risk reduction | ||||
| Endpoint | Events rate | Absolute risk reduction (ARR) |
||
|---|---|---|---|---|
| Studied treat. | Control treat. | |||
Reference(s)
| Trials register # | NA |
-
Gonz�lez-Fajardo JA, Martin-Pedrosa M, Castrodeza J, Tamames S, Vaquero-Puerta C.
Effect of the anticoagulant therapy in the incidence of post-thrombotic syndrome and recurrent thromboembolism: Comparative study of enoxaparin versus coumarin..
J Vasc Surg 2008;48:953-9
Pubmed
|
Hubmed
| Fulltext
(c) 2004-2010 TrialResults-center - All Rights Reserved
Tweet this
notify a friend